F-1/A: Jyong Biotech Seeks Nasdaq Listing with Initial Public Offering

Jyong Biotech, a Taiwan-based biotechnology company, is planning an initial public offering of its ordinary shares, aiming for a Nasdaq listing under the symbol MENS.

Summary

• Jyong Biotech Ltd., a Cayman Islands exempted holding company with operations in Taiwan, Singapore, Hong Kong, and China, is planning an initial public offering (IPO) of 2,666,667 ordinary shares.
• The company anticipates the IPO price to be between US$7.50 and US$8.50 per share.
• Jyong Biotech has applied to list its ordinary shares on the Nasdaq Global Market under the symbol MENS, but approval is not yet assured.
• The company is currently developing botanical drug candidates, including MCS-2 for benign prostate hyperplasia (BPH), PCP for prostate cancer prevention, and IC for interstitial cystitis.
• MCS-2, the lead drug candidate, has undergone Phase III clinical trials, but one U.S. trial failed to meet its primary efficacy endpoint.
• The company voluntarily withdrew its NDA for MCS-2 to address U.S. FDA concerns and is working to demonstrate comparability between API-1 and API-2.
• The company has a net working capital deficit of approximately US$12.5 million and US$11.7 million as of December 31, 2023 and June 30, 2024, respectively, and has not yet generated revenue.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company is involved in legal proceedings, including a dispute with a shareholder and a claim from the Taizhou Resources Bureau, which could have a material adverse effect on its business.
• The company faces economic and political risks associated with doing business in Taiwan, particularly due to geopolitical tensions with China.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has promising drug candidates and a clear strategy, it also faces significant challenges, including regulatory hurdles, financial constraints, and legal proceedings. The overall sentiment is cautiously optimistic, but with a high degree of uncertainty.

Positives

• The company has a diverse drug portfolio and pipeline focusing on urinary system diseases.
• The company has integrated in-house capabilities for pharmaceutical innovation.
• The company has a visionary and experienced management and R&D team.
• The company has Phase III experience to accelerate collaboration with pharmaceutical companies.

Negatives

• The company has not yet reached the commercialization stage for any of its drug candidates.
• The company's drug candidates mainly focus on the treatment of urinary system diseases.
• The company's business is highly dependent on obtaining marketing approval for or successfully commercializing its core drug candidate, MCS-2.
• The company may not succeed in the market with substantial competition and rapid technological change.
• The company has a net working capital deficit of approximately US$12.5 million and US$11.7 million as of December 31, 2023 and June 30, 2024, respectively, and has not yet generated revenue.
• There is substantial doubt about the company's ability to continue as a going concern.

Risks

• The company's business is highly dependent on the success of its core drug candidate, MCS-2.
• The U.S. FDA has rarely approved botanical drug products.
• Clinical development involves a lengthy and expensive process with an uncertain outcome.
• The company may encounter delays or difficulties enrolling and retaining patients in its clinical trials.
• The company's drug candidates may cause serious adverse, undesirable or unacceptable side effects.
• The manufacture of the company's botanical drug products is a complex process.
• The company faces economic and political risks associated with doing business in Taiwan, particularly due to the geopolitical tension between Taiwan and PRC.
• The company is required to comply with extensive regulations and hold a number of permits and licenses to carry on its business in Taiwan.
• The company's future success depends on its ability to attract, retain and motivate senior management and qualified scientific employees.
• The company is involved in legal proceedings, including a dispute with a shareholder and a claim from the Taizhou Resources Bureau.

Future Outlook

The company plans to advance the clinical development of MCS-2, leverage differentiated approaches to advance other drug candidates, establish integrated launch capabilities, and deepen its pipeline in existing therapeutic areas.

Industry Context

The global pharmaceutical market is expected to grow, driven by an aging population and increased healthcare expenditure. The global BPH drugs market is also expected to increase, driven by an increase in the number of older males and an increase in patients' awareness of medical care.

Comparison to Industry Standards

• The document mentions Veregen and Mytesi as the only two botanical drug products approved by the U.S. FDA for marketing as prescription drugs.
• The document references Frost & Sullivan data on the global BPH drugs market, which reached US$4.1 billion in 2020, and the global prostate cancer market, which reached US$12.6 billion in 2019.
• The document does not provide a direct comparison of Jyong Biotech's results to specific comparable companies or projects.

Legal Proceedings

• The company is a party to a legal dispute against one of its shareholders, the Taizhou City Optimization and Upgrade Investment Partnership (Limited Partnership), concerning a claim of redemption.
• The company's PRC subsidiary, Innovative Biotech Co., Ltd., is involved in a civil complaint filed by the Taizhou Bay New District Administrative Committee, claiming that Innovative Biotech has materially breached the 2019 Taizhou Agreement by failing to initiate and conclude the construction of the Factory Project in accordance with the schedule stipulated by the 2019 Taizhou Agreement and the Land Use Right Agreement.

Related Party Transactions

• The company has entered into a number of transactions with related parties, including leases with landlord entities in which Ms. Kuo has or had a significant ownership interest.
• From February 2021 to November 2021, the Company entered into several loan agreements with Nobel Consumer Corporation, which is managed by a related party of the Company.

Stakeholder Impact

• Shareholders may experience dilution of their ownership interest due to the issuance of new shares in the IPO.
• Shareholders may face difficulties in protecting their interests due to the company's incorporation in the Cayman Islands.
• Employees may be affected by the company's ability to attract, retain, and motivate senior management and qualified scientific employees.
• Customers may benefit from the development and commercialization of new drugs for urinary system diseases.
• Suppliers may benefit from increased business with the company as it expands its operations.
• Creditors may be affected by the company's ability to repay its debts.

Next Steps

• The company plans to conduct additional Phase III trial and Phase I PK study in the US using API-2 to support its NDA re-submission.
• The company will have a separate meeting with the U.S. FDA to discuss the Chemistry and Manufacturing, and Control (CMC) information for API-2, to determine whether API-1 and API-2 are comparable.
• The company will discuss the statistical results of the PCP using API-2 with Taiwan regulator and proceed with the Phase III PCP study if the U.S. FDA accepts such results and determines that API-1 and API-2 are comparable.

Key Dates

Keywords

Jyong Biotech, IPO, Nasdaq, MCS-2, BPH, LUTS, PCP, Prostate Cancer, IC, Interstitial Cystitis, Botanical Drug, Clinical Trials, FDA, API-1, API-2